New drugs and novel targets for treatment of invasive fungal infections in patients with cancer.
Invasive fungal infections have emerged as important causes of morbidity and mortality in profoundly immunocompromised patients with cancer. Current treatment strategies for these infections are limited by antifungal resistance, toxicity, drug interactions, and expense. In order to overcome these limitations, new antifungal compounds are being developed, which may improve our therapeutic armamentarium for prevention and treatment of invasive mycoses in high-risk patients with neoplastic diseases.
Chiou
C C
CC
National Cancer Institute, Bethesda, Maryland, USA.
Groll
A H
AH
Walsh
T J
TJ
D000077612:Anidulafungin; D000935:Antifungal Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D054714:Echinocandins; D006801:Humans; D016867:Immunocompromised Host; D055666:Lipopeptides; D008074:Lipoproteins / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000077551:Micafungin; D009181:Mycoses / Q000188:drug therapy* / Q000209:etiology; D009369:Neoplasms / Q000150:complications* / Q000382:microbiology; D009894:Opportunistic Infections / Q000188:drug therapy; D010456:Peptides, Cyclic / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D011743:Pyrimidines / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D014230:Triazoles / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D065819:Voriconazole
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D008074:Lipoproteins; D010456:Peptides, Cyclic; D011743:Pyrimidines; D014230:Triazoles; D000077612:Anidulafungin; D065819:Voriconazole; D000077551:Micafungin